<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719112438061</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719112438061</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Chwalisz</surname>
<given-names>Kristof</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719112438061">1</xref>
<xref ref-type="corresp" rid="corresp1-1933719112438061"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Surrey</surname>
<given-names>Eric</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1933719112438061">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stanczyk</surname>
<given-names>Frank Z.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-1933719112438061">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1933719112438061">
<label>1</label>Abbott Laboratories, Abbott Park, IL, USA</aff>
<aff id="aff2-1933719112438061">
<label>2</label>Colorado Center for Reproductive Medicine, Lone Tree, CO, USA</aff>
<aff id="aff3-1933719112438061">
<label>3</label>Departments of Obstetrics and Gynecology, and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA</aff>
<author-notes>
<corresp id="corresp1-1933719112438061">Kristof Chwalisz, Abbott Laboratories, 200 Abbott Park Dr, Abbott Park, IL 60064, USA Email: <email>kristof.chwalisz@abbott.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>563</fpage>
<lpage>571</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation. Through its estrogenic activity, NETA exerts beneficial effects on bone mineral density and vasomotor symptoms in women treated with GnRHa. In addition, NETA exhibits strong endometrial antiproliferative effects, which may result in further benefits for the endometriosis patient population. However, NETA add-back may be associated with progestogenic side effects and may lower high-density lipoprotein due to androgenic activity. These effects must be balanced with the overall benefits of NETA add-back therapy.</p>
</abstract>
<kwd-group>
<kwd>norethindrone acetate</kwd>
<kwd>GnRH agonist</kwd>
<kwd>endometriosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719112438061">
<title>Introduction</title>
<p>Endometriosis is a chronic estrogen-dependent disease that occurs in approximately 10% of reproductive age women.<sup>
<xref ref-type="bibr" rid="bibr1-1933719112438061">1</xref>
</sup> Endometriosis may cause painful symptoms, including dysmenorrhea, chronic nonmenstrual pelvic pain, and dyspareunia, as well as infertility. The primary treatment objective for women with endometriosis who are not trying to conceive is the management of pelvic pain. Therapeutic options for symptomatic endometriosis include oral contraceptives, nonsteroidal antiinflammatory drugs, high-dose progestins, androgenic agents (eg, danazol), and gonadotropin-releasing hormone agonists (GnRHa). Gonadotropin releasing hormone agonists, danazol, and high-dose progestins are generally used as a second-line therapy.<sup>
<xref ref-type="bibr" rid="bibr2-1933719112438061">2</xref>
</sup> Other agents including GnRH antagonists, aromatase inhibitors, and both estrogen and progesterone receptor (PR) modulators are under investigation but remain experimental.</p>
<p>Several GnRHa have been shown to be effective in reducing the pelvic pain associated with endometriosis, often when other medical therapies have failed.<sup>
<xref ref-type="bibr" rid="bibr3-1933719112438061">3</xref>
</sup> However, treatment with GnRHa is associated with hypoestrogenic side effects, including progressive bone loss and vasomotor symptoms, such as hot flashes and headache and vaginal dryness. Therefore, use of GnRHa as a monotherapy (ie, without hormonal add-back therapy) is limited to a single 6-month course of therapy in the United States. In the early 1990s, several investigators proposed using hormonal add-back therapy to ameliorate hypoestrogenic symptoms during GnRHa therapy in women with endometriosis while preserving the therapeutic efficacy.<sup>
<xref ref-type="bibr" rid="bibr4-1933719112438061">4</xref>
</sup> Hormonal add-back therapy may enhance compliance and potentially prolong the duration of GnRHa therapy. Several studies utilizing different hormonal and nonhormonal add-back regimens, including monotherapy with various progestins, different estrogen–progestin combinations, estrogen monotherapy, and tibolone (in Europe), have been published.<sup>
<xref ref-type="bibr" rid="bibr5-1933719112438061">5</xref>
<xref ref-type="bibr" rid="bibr6-1933719112438061"/>–<xref ref-type="bibr" rid="bibr7-1933719112438061">7</xref>
</sup> The majority of these studies have confirmed the efficacy of add-back therapy in terms of a reduction in vasomotor symptoms and protective effects on the bone with minimal negative effects on GnRHa-induced pain relief. In 1999, the Add-Back Consensus Working Group recommended the use of an appropriate add-back therapy with GnRHa treatment based on a systematic review of scientific evidence.<sup>
<xref ref-type="bibr" rid="bibr8-1933719112438061">8</xref>
</sup> Based on the results from randomized controlled studies, the progestin norethindrone acetate (NETA; known as norethisterone acetate in Europe) was approved by the US Food and Drug Administration at a daily dose of 5 mg in combination with the synthetic GnRHa, leuprolide acetate, as an add-back therapy in women with endometriosis.<sup>
<xref ref-type="bibr" rid="bibr9-1933719112438061">9</xref>
</sup> Initially, a 6-month course of leuprolide acetate plus NETA 5 mg is recommended, with up to 6 months of additional therapy as needed for recurrence of symptoms.<sup>
<xref ref-type="bibr" rid="bibr4-1933719112438061">4</xref>,<xref ref-type="bibr" rid="bibr10-1933719112438061">10</xref>
</sup> The use of add-back therapy has been recommended by several national and international professional gynecological societies, including the American College of Obstetricians and Gynecologists<sup>
<xref ref-type="bibr" rid="bibr11-1933719112438061">11</xref>
</sup> and European Society of Human Reproduction and Embryology (ESHRE).<sup>
<xref ref-type="bibr" rid="bibr12-1933719112438061">12</xref>
</sup> However, these recommendations do not specify the preferred add-back therapies, and there is some confusion regarding progestin-only add-back therapy. Although add-back therapy with NETA 5 mg is recommended in the United States, inconsistent results have been found with NETA when used at lower doses and with other progestins when used without an estrogen as an add-back therapy to GnRHa. These inconsistencies have prompted the updated ESHRE Guideline for Diagnosis and Treatment of Endometriosis to state that progestogen-only add-back therapy does not protect bone density.<sup>
<xref ref-type="bibr" rid="bibr1-1933719112438061">1</xref>
</sup> We believe that these discrepancies are due to the limited knowledge of the hormonal properties of various progestins because publications have historically grouped all progestins together into the category of “progestin-only add-back therapy,” without analyzing their unique hormonal activities.</p>
<p>Despite guideline recommendations, add-back therapy is prescribed in only one third of women with endometriosis who are treated with leuprolide acetate, according to a retrospective analysis of a large pharmacy claims database.<sup>
<xref ref-type="bibr" rid="bibr13-1933719112438061">13</xref>
</sup> Reasons for this low utilization of add-back therapy are unclear and probably multifactorial. The reasons may include limited understanding of the benefits and risks of add-back therapy and its mechanism of action by physicians and patients, lack of updated guidelines, and confusion due to the multitude of add-back regimens evaluated to date.</p>
<p>In this article, we discuss the hormonal profile of NETA, providing a rationale for why this compound, in contrast to other progestins, is effective as an add-back regimen without estrogen supplementation. We focus on the estrogenic and androgenic properties of NETA and their potential implications for both efficacy and safety for add-back therapy.</p>
</sec>
<sec id="section2-1933719112438061">
<title>Norethindrone Acetate</title>
<sec id="section3-1933719112438061">
<title>Hormonal Profile</title>
<p>It is a common misconception that all progestogens have similar mechanisms of action and produce similar effects in vivo. It is important to note that progesterone is the only naturally occurring hormone that belongs to the larger class of progestogens. In addition, there is a diverse group of synthetic progestogens (progestins) available for therapeutic use, which have distinct actions based on their affinity for steroid receptors other than the PR (ie, estrogen, androgen, and glucocorticoid receptors). The NETA was one of the first orally active progestins that found a broad application in oral contraception, postmenopausal hormone therapy, and gynecologic therapy. After oral administration, NETA is rapidly converted to the parent compound norethindrone (NET) by esterases during intestinal and hepatic first-pass metabolism.<sup>
<xref ref-type="bibr" rid="bibr14-1933719112438061">14</xref>
</sup> Both NETA and NET compounds are structurally related to testosterone and are characterized by the presence of an ethinyl group at carbon 17 and the absence of a methyl group at carbon 10 (<xref ref-type="fig" rid="fig1-1933719112438061">Figure 1</xref>). These modifications of the testosterone molecule resulted in an acquisition of progestogenic and oral activity (testosterone is not orally active) and dramatically reduced its androgenic activity. Both compounds belong to a larger family of progestins called estranes, which are characterized by an 18-carbon steroid nucleus that comprises the parent compound, estrane. Tibolone also belongs to this group and has a chemical structure that can be viewed as a derivative of NET (<xref ref-type="fig" rid="fig1-1933719112438061">Figure 1</xref>). The structural features of NETA are important with regard to its pharmacokinetic and pharmacologic profiles in women. In vivo, both NETA and NET exhibit strong tissue-specific progestogenic, estrogenic or antiestrogenic, and androgenic effects.<sup>
<xref ref-type="bibr" rid="bibr15-1933719112438061">15</xref>
</sup> Similarly, tibolone is a prodrug of progestogenic, estrogenic, and androgenic metabolites that mediate its pharmacodynamic effects in vivo.<sup>
<xref ref-type="bibr" rid="bibr16-1933719112438061">16</xref>
</sup> In contrast, medroxyprogesterone acetate (MPA), the most commonly prescribed progestin in the United States, does not have any estrogenic properties as partially evidenced by reports of decreased bone mineral density (BMD) in women using depot MPA<sup>
<xref ref-type="bibr" rid="bibr17-1933719112438061">17</xref>
</sup> and increased fracture risk,<sup>
<xref ref-type="bibr" rid="bibr18-1933719112438061">18</xref>
</sup> and, unlike most other progestins, expresses glucocorticoid activity.<sup>
<xref ref-type="bibr" rid="bibr19-1933719112438061">19</xref>
</sup>
</p>
<fig id="fig1-1933719112438061" position="float">
<label>Figure 1.</label>
<caption>
<p>Chemical structures of norethindrone (or norethisterone) acetate (NETA), norethindrone (or norethisterone [NET]), tibolone, and progesterone.</p>
</caption>
<graphic alternate-form-of="fig1-1933719112438061" xlink:href="10.1177_1933719112438061-fig1.tif"/>
</fig>
</sec>
<sec id="section4-1933719112438061">
<title>Clinical Pharmacology</title>
<p>The pharmacokinetic profile of NETA largely depends on that of the parent compound NET, which has a relatively high oral bioavailability of 46% to 73% and a half-life of approximately 8 hours after oral administration.<sup>
<xref ref-type="bibr" rid="bibr20-1933719112438061">20</xref>,<xref ref-type="bibr" rid="bibr21-1933719112438061">21</xref>
</sup> In the liver, NET undergoes extensive ring A reduction to dihydro- and tetrahydro-norethindrone metabolites, as well as aromatization and conjugation.<sup>
<xref ref-type="bibr" rid="bibr22-1933719112438061">22</xref>
</sup> The ability of NET to undergo aromatization is particularly important for its pharmacologic profile in vivo because one of its metabolites is ethinyl estradiol, which is one of the most potent synthetic estrogens. This conversion was first demonstrated in postmenopausal women following oral administration of relatively high doses of NETA.<sup>
<xref ref-type="bibr" rid="bibr23-1933719112438061">23</xref>
</sup> The mean conversion ratio of NETA-derived NET to ethinyl estradiol in this study was 0.7% to 1% at doses of 5 and 10 mg NETA, respectively, which translates to an oral dose equivalent of approximately 6 µg of ethinyl estradiol per milligram of NETA. These data suggested that 5 mg NETA is equivalent to an oral dose of 20 to 30 µg of ethinyl estradiol, taking into account interindividual variability. More recently, formation of ethinyl estradiol from NETA-derived NET was confirmed in premenopausal women who were treated with 10, 20, and 40 mg of NETA for 7 days during the early proliferative phase of the menstrual cycle (<xref ref-type="fig" rid="fig2-1933719112438061">Figure 2</xref>).<sup>
<xref ref-type="bibr" rid="bibr24-1933719112438061">24</xref>
</sup> It was calculated that for 10 mg NETA, the approximate conversion to ethinyl estradiol<sup>
<xref ref-type="bibr" rid="bibr24-1933719112438061">24</xref>
</sup> was 0.2%. These observed differences in the conversion rates of NETA to ethinyl estradiol may be due to differences in menopausal status between the women in the 2 studies and/or in body mass index, which has been shown to affect contraceptive efficacy.<sup>
<xref ref-type="bibr" rid="bibr25-1933719112438061">25</xref>
</sup> Although the results of the more recent study showed a lower conversion rate, both studies demonstrate that in women, significant amounts of ethinyl estradiol are formed from NETA, which exert estrogenic effects on bone and the central nervous system (CNS).</p>
<fig id="fig2-1933719112438061" position="float">
<label>Figure 2.</label>
<caption>
<p>Formation of ethinylestradiol (EE<sub>2</sub>) after oral administration of NETA in premenopausal women (Adapted with permission from Chu et al<sup><xref ref-type="bibr" rid="bibr24-1933719112438061">24</xref></sup>).</p>
</caption>
<graphic alternate-form-of="fig2-1933719112438061" xlink:href="10.1177_1933719112438061-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section5-1933719112438061">
<title>Pharmacologic Basis of Add-Back Therapy: Role of Estrogen and Progesterone</title>
<p>Decreased BMD and onset of vasomotor symptoms, primarily hot flashes, are the key clinical concerns of GnRHa therapy in women with endometriosis. Gonadotropin releasing hormone agonists GnRHa treatment suppresses the ovarian production of estrogen, progesterone, and to some extent androgens. Thus, the most suitable hormonal profile for add-back therapy has been an area of active research.</p>
<p>It is generally accepted that menopausal symptoms and postmenopausal bone loss are primarily related to estrogen deprivation. Historically, little attention has been paid in the literature to progesterone and ovarian androgens. In fact, the “estrogen threshold hypothesis,” which provides the rationale for add-back therapy, does not address progesterone or ovarian androgens at all.<sup>
<xref ref-type="bibr" rid="bibr26-1933719112438061">26</xref>
</sup> This hypothesis is based on the observation that various target tissues exert different sensitivity to circulating estrogens, and the assumption that restoring estrogen concentrations to early follicular levels during GnRHa therapy should control endometriosis pain without inducing loss of BMD and other symptoms of estrogen deprivation. Consistent with this theory, studies of various steroid hormone receptor agonists and selective steroid receptor modulators (eg, selective estrogen receptor modulators, selective PR modulators, and selective androgen receptor modulators) clearly demonstrate that various target tissues exhibit different levels of sensitivity to steroid hormones.<sup>
<xref ref-type="bibr" rid="bibr27-1933719112438061">27</xref>
<xref ref-type="bibr" rid="bibr28-1933719112438061"/>–<xref ref-type="bibr" rid="bibr29-1933719112438061">29</xref>
</sup> The sensitivity of target organs to estrogen or other steroid hormones is regulated not only by the tissue concentration of the specific receptors but also by tissue-specific expression of nuclear cofactors, coactivators, and corepressors. The relative balance of coactivator and corepressor expression, within a given target cell, seems to be crucial in determining the gene-, cell-, and tissue-specific responses to steroid receptor ligands.<sup>
<xref ref-type="bibr" rid="bibr28-1933719112438061">28</xref>
</sup> It has been well established that bone is a highly estrogen-sensitive tissue.<sup>
<xref ref-type="bibr" rid="bibr30-1933719112438061">30</xref>
</sup> This observation was demonstrated in clinical studies conducted in postmenopausal women who were treated with low estrogen doses, which resulted in antiresorptive activity in bones with minimal stimulation of endometrial proliferation.<sup>
<xref ref-type="bibr" rid="bibr31-1933719112438061">31</xref>
</sup> Studies in postmenopausal women have clearly shown that there is a ranking of estrogenic effects in various tissues, with bone being the most sensitive tissue (prevention of resorption), followed by the CNS (reduction of vasomotor symptoms), uterine and vaginal epithelium (increased tissue proliferation), and liver (increased production of sex hormone-binding globulin, corticosteroid-binding globulin and clotting factors, and altered lipids).<sup>
<xref ref-type="bibr" rid="bibr31-1933719112438061">31</xref>
<xref ref-type="bibr" rid="bibr32-1933719112438061"/>–<xref ref-type="bibr" rid="bibr33-1933719112438061">33</xref>
</sup>
</p>
<sec id="section6-1933719112438061">
<title>GnRHa-Induced Bone Loss: Effects of Estrogen and Progesterone</title>
<p>Bone tissue undergoes constant remodeling, which is characterized by the process of resorption and subsequent bone formation. Both bone resorption and formation are controlled, in part, by steroid hormones. Evidence from animal and clinical studies indicates that both estrogens and androgens play an important role in bone remodeling, whereas progesterone does not seem to have a significant role in this process. Estrogens prevent bone resorption by inhibiting the function of osteoclasts, whereas androgens stimulate bone formation mainly by exerting an anabolic effect on osteoblasts. Although the effects of estrogen and androgens on the skeleton are well documented, those of progesterone and progestins are controversial.<sup>
<xref ref-type="bibr" rid="bibr34-1933719112438061">34</xref>
</sup> A recent animal model study of PR signaling in bone, conducted in homozygous female PR knockout (PRKO) mice lacking gene expression of A and B isoforms<sup> </sup>of the PR, provided further insights into the mechanism of action of progesterone in bone.<sup>
<xref ref-type="bibr" rid="bibr35-1933719112438061">35</xref>
</sup> Tibia longitudinal<sup> </sup>bone growth was normal in PRKO mice, and a tendency toward elevation in bone formation<sup> </sup>was observed, even in adolescent animals.<sup>
<xref ref-type="bibr" rid="bibr35-1933719112438061">35</xref>
</sup> This study showed that PR signaling is not essential<sup> </sup>for bone growth and turnover in mice.</p>
<p>The experience with various postmenopausal hormonal therapies used for osteoporosis prevention, including studies with both estrogen monotherapy and estrogen–progestin combinations, clearly indicates that the inhibition of bone resorption is solely due to the estrogen effect of these preparations, whereas most progestins have shown neutral effects on bone. In fact, estrogen monotherapy seems to be equally effective as combined estrogen and progestin therapy in preventing bone loss, which suggests that progestin treatment neither enhances nor attenuates the antiresorptive effect of an estrogen.<sup>
<xref ref-type="bibr" rid="bibr36-1933719112438061">36</xref>
</sup> Although a few early clinical studies suggested that there may be some beneficial effects of progesterone and progestins on bone,<sup>
<xref ref-type="bibr" rid="bibr37-1933719112438061">37</xref>
</sup> more recent clinical trials do not provide evidence that progesterone or “pure” (PR-selective) progestins improve bone density in postmenopausal, hysterectormized, or amenorrheic women.<sup>
<xref ref-type="bibr" rid="bibr38-1933719112438061">38</xref>
</sup>
</p>
<p>The role of androgen receptor (AR)-mediated effects of androgenic progestins (eg, NETA, tibolone, levonorgestrel, etc) on bone in women remains unclear. In mice, loss of the AR results in bone loss in males but not females.<sup>
<xref ref-type="bibr" rid="bibr39-1933719112438061">39</xref>
</sup> Furthermore, in men with androgen insensitivity syndrome, osteopenia is observed, which may be related to defective androgen action, estrogen deficiency, or a combination of the two.<sup>
<xref ref-type="bibr" rid="bibr40-1933719112438061">40</xref>
</sup> However, osteroporosis associated with incomplete epiphyseal closure was also described in a man with an estrogen receptor mutation.<sup>
<xref ref-type="bibr" rid="bibr41-1933719112438061">41</xref>
</sup> In postmenopausal women, NET, NETA, and tibolone are the only progestins that have been shown to prevent bone resorption in the absence of estrogen.<sup>
<xref ref-type="bibr" rid="bibr42-1933719112438061">42</xref>,<xref ref-type="bibr" rid="bibr43-1933719112438061">43</xref>
</sup> An early report also indicated that long-term therapy with NET 5 mg restores bone loss in patients with untreated hyperparathyroidism and osteoporosis.<sup>
<xref ref-type="bibr" rid="bibr44-1933719112438061">44</xref>
</sup> It is likely that both NETA and tibolone exert antiresorptive activity in bone mostly via their estrogenic metabolites. However, there is some evidence in the literature that NETA also exerts anabolic effects on bone via AR signaling. Treatment of postmenopausal women with NETA 5 mg twice daily for 2 years not only prevented loss of bone mineral content but also resulted in an increase of 1.65% annually.<sup>
<xref ref-type="bibr" rid="bibr42-1933719112438061">42</xref>
</sup> In contrast, the placebo group showed a marked decrease of bone mineral content of approximately 5% annually.<sup>
<xref ref-type="bibr" rid="bibr42-1933719112438061">42</xref>
</sup> In a separate study, treatment of postmenopausal women with a sequential regimen of estradiol 1 to 4 mg (first phase) and NETA 1 mg (second phase), only had an effect on serum markers of bone formation in the NETA-containing combination phase.<sup>
<xref ref-type="bibr" rid="bibr45-1933719112438061">45</xref>
</sup> Moreover, long-term continuous combined treatment with estradiol and NETA has been shown to result in a higher lumbar spine bone density than sequential addition of NETA.<sup>
<xref ref-type="bibr" rid="bibr46-1933719112438061">46</xref>,<xref ref-type="bibr" rid="bibr47-1933719112438061">47</xref>
</sup>
</p>
<p>In contrast, the progestin MPA actually induces bone loss in premenopausal women<sup>
<xref ref-type="bibr" rid="bibr17-1933719112438061">17</xref>,<xref ref-type="bibr" rid="bibr48-1933719112438061">48</xref>,<xref ref-type="bibr" rid="bibr49-1933719112438061">49</xref>
</sup> and reduces the antiresorptive effect of estrogen on spine mineral density in postmenopausal women.<sup>
<xref ref-type="bibr" rid="bibr37-1933719112438061">37</xref>
</sup> The BMD loss observed during long-term depot MPA use for contraception is most likely due to the antigonadotropic effect of this compound. However, the contribution of the antiglucocorticoid effect of this compound cannot be ruled out. Unlike other progestins, MPA binds to the glucocorticoid receptor and exerts glucocorticoid-mediated effects in vivo, which appear to be responsible for the treatment-related bone loss.<sup>
<xref ref-type="bibr" rid="bibr15-1933719112438061">15</xref>
</sup>
</p>
<p>Some of the most compelling studies on the role of PR in BMD loss in premenopausal women were conducted by Fernandez et al and Roux et al. These authors evaluated the effects of the “pure” progestin promegestone alone and in combination with estradiol, as add-back therapy for endometriosis.<sup>
<xref ref-type="bibr" rid="bibr50-1933719112438061">50</xref>,<xref ref-type="bibr" rid="bibr51-1933719112438061">51</xref>
</sup> In these studies, BMD decreases were seen in both groups but the changes were less clinically significant in the promegestone–estradiol add-back group compared with the promegestone-only add-back group. The proportion of individuals with clinically relevant decrease in BMD (&gt;2.8% change) at the lumbar spine and total hip were 90% and 60% in the promegestone-only add-back group and 34.5% and 19.4% in the promegestone-estradiol group, respectively. These studies indicate that the “pure” PR agonist, promegestone, has little, if any, effect on bone in GnRHa-treated, premenopausal women with endometriosis.</p>
</sec>
<sec id="section7-1933719112438061">
<title>Vasomotor Symptoms: Effects of Estrogen and Progestins</title>
<p>Evidence from clinical studies in postmenopausal women indicates that both estrogen and progestin add-back therapies reduce vasomotor symptoms. Although there is a general consensus in the literature that estrogen is the most effective treatment of vasomotor symptoms in postmenopausal women, there are also studies showing that MPA dose-dependently enhances the efficacy of estrogen for reducing hot flashes.<sup>
<xref ref-type="bibr" rid="bibr52-1933719112438061">52</xref>
</sup> In addition, megestrol acetate, a progestin without any estrogenic activity, is frequently used to manage hot flashes in men with prostate cancer undergoing androgen deprivation therapy and in women with breast cancer who cannot use estrogens.<sup>
<xref ref-type="bibr" rid="bibr53-1933719112438061">53</xref>,<xref ref-type="bibr" rid="bibr54-1933719112438061">54</xref>
</sup> These data suggest that there are beneficial effects of progestins on hot flashes, which are mediated by the PR. However, to date, there have been no comparative trials that allow the evaluation of differences in the effects of various progestins on vasomotor symptoms.</p>
</sec>
<sec id="section8-1933719112438061">
<title>Effects of NETA Endometrial Proliferation</title>
<p>Normal endometrium is controlled by a balance of estrogen and progesterone. Estrogen stimulates cell growth and the upregulation of PR. Progesterone balances the effects of estrogen on the endometrium by downregulating both ER and PR.<sup>
<xref ref-type="bibr" rid="bibr55-1933719112438061">55</xref>
</sup> In postmenopausal women, a progestin is generally included in hormone therapy to prevent the “unopposed” proliferative effects of estrogen. The effective daily dose of NETA in preventing endometrial hyperplasia is 0.5 mg or less in postmenopausal women treated with an estrogen.<sup>
<xref ref-type="bibr" rid="bibr56-1933719112438061">56</xref>
</sup> In postmenopausal women, doses of NETA as low as 0.1 to 0.5 mg per day are effective in preventing endometrial hyperplasia in women treated with 0.5 and 1 mg estradiol per day, respectively.<sup>
<xref ref-type="bibr" rid="bibr57-1933719112438061">57</xref>
</sup> These data suggest that NETA exerts a strong endometrial antiproliferative effects at low doses, which may be relevant to the endometriosis population.</p>
</sec>
<sec id="section9-1933719112438061">
<title>Effects on Breast</title>
<p>Progesterone is a mitogen in breast epithelial cells.<sup>
<xref ref-type="bibr" rid="bibr58-1933719112438061">58</xref>
</sup> Mitotic activity in normal breast tissue peaks during the luteal phase and progestins increase mammographic breast density in postmenopausal women, an effect that is accompanied by an increase in the expression of proliferation markers.<sup>
<xref ref-type="bibr" rid="bibr59-1933719112438061">59</xref>
<xref ref-type="bibr" rid="bibr60-1933719112438061"/>–<xref ref-type="bibr" rid="bibr61-1933719112438061">61</xref>
</sup> Furthermore, continuous administration of estrogen–progestin regimens, but not estrogen treatment alone, was associated with a slight, but significant, increase in breast cancer risk as reported by the Women’s Health Initiative (WHI) study and other clinical studies in postmenopausal women.<sup>
<xref ref-type="bibr" rid="bibr62-1933719112438061">62</xref>,<xref ref-type="bibr" rid="bibr63-1933719112438061">63</xref>
</sup> These findings were recently confirmed by a reanalysis of the WHI data demonstrating a long-term increased risk of developing invasive breast cancer in postmenopausal women treated with conjugated equine estrogens in combination with MPA.<sup>
<xref ref-type="bibr" rid="bibr64-1933719112438061">64</xref>
</sup> Small, observational studies have suggested that hormonal therapy containing NETA may increase mammographic breast density and risk of breast cancer in postmenopausal women.<sup>
<xref ref-type="bibr" rid="bibr65-1933719112438061">65</xref>,<xref ref-type="bibr" rid="bibr66-1933719112438061">66</xref>
</sup> However, in postmenopausal women, the effects of adding a progestogen to estrogen hormone therapy on breast cancer risk are confounded by the unknown effects of the dose, treatment duration, and route of administration. In addition, baseline risk in this population may be greater due to the patient’s age and established lifestyle habits.</p>
<p>There is limited data on the risk of breast cancer in premenopausal women who are using progestins alone for hormonal contraception; however, the overall risk of breast cancer in this patient population is low.<sup>
<xref ref-type="bibr" rid="bibr67-1933719112438061">67</xref>
</sup> Numerous studies have investigated the relationship between combined (progestin + estrogen) oral contraceptives and risk of breast cancer. Data, primarily from observational studies, have not conclusively demonstrated an increased risk of breast cancer.<sup>
<xref ref-type="bibr" rid="bibr68-1933719112438061">68</xref>
</sup> There is some evidence that the use or recent use of oral contraceptives may cause a modest increase in the risk of breast cancer; however, the absolute number of breast cancer cases are low.<sup>
<xref ref-type="bibr" rid="bibr69-1933719112438061">69</xref>
</sup> Furthermore, there may be enhanced diagnosis of these cases because of detection/surveillance bias or accelerated growth of already present malignancies. In addition, there is no evidence that duration of use (up to 15 years),<sup>
<xref ref-type="bibr" rid="bibr70-1933719112438061">70</xref>
</sup> past use of oral contraceptive, or higher dose oral contraceptives increases risk of breast cancer.<sup>
<xref ref-type="bibr" rid="bibr69-1933719112438061">69</xref>,<xref ref-type="bibr" rid="bibr71-1933719112438061">71</xref>
</sup> There is no specific information available on the use of NETA and on risk of breast cancer in premenopausal women. However, a cohort study of 1150 premenopausal French women with benign breast disease showed a reduction in the risk of breast cancer by approximately 50% in women treated with 19-nortestosterone derivatives, whereas progesterone derivatives had no effect.<sup>
<xref ref-type="bibr" rid="bibr72-1933719112438061">72</xref>
</sup> The authors suggested that androgenic progestins may have beneficial effect on breast in premenopausal women.<sup>
<xref ref-type="bibr" rid="bibr72-1933719112438061">72</xref>
</sup> However, more studies are needed to confirm this assumption.</p>
</sec>
<sec id="section10-1933719112438061">
<title>Metabolic and Cardiovascular Effects</title>
<p>For many years, estrogens were believed to have vasculoprotective effects based on preclinical evidence and observational studies. This belief was challenged by the WHI study,<sup>
<xref ref-type="bibr" rid="bibr62-1933719112438061">62</xref>
</sup> although newer results from this study showed that women who initiated hormone therapy closer to menopause tended to have reduced coronary heart disease (CHD) risk compared with the increase in CHD risk among women more distant from menopause.<sup>
<xref ref-type="bibr" rid="bibr73-1933719112438061">73</xref>
</sup> In addition, menopause has a negative effect on the lipid profile, which is reversed with the addition of estrogen therapy. Overall, when given in combination with estrogen, progestins do not have a large impact on the estrogen effects on low-density lipoprotein and total cholesterol, but they may decrease high-density lipoprotein (HDL) and triglycerides.<sup>
<xref ref-type="bibr" rid="bibr74-1933719112438061">74</xref>
</sup> In animals, PRs have been identified in the vascular endothelium and vascular smooth muscle, where they are involved in cell growth and gene transcription. Progesterone has been demonstrated to enhance the vasodilatory property of estrogen in the coronary arteries of animal models.<sup>
<xref ref-type="bibr" rid="bibr75-1933719112438061">75</xref>
<xref ref-type="bibr" rid="bibr76-1933719112438061"/>
<xref ref-type="bibr" rid="bibr77-1933719112438061"/>–<xref ref-type="bibr" rid="bibr78-1933719112438061">78</xref>
</sup> Notably, NETA also acts as a vasodilator in the coronary vasculature of animal models, whereas MPA causes vasoconstriction.<sup>
<xref ref-type="bibr" rid="bibr79-1933719112438061">79</xref>,<xref ref-type="bibr" rid="bibr80-1933719112438061">80</xref>
</sup>
</p>
<p>Because NETA has androgenic activity, it exerts potential negative effects on the lipid profile and insulin resistance, which are known surrogate factors for cardiovascular disease. However, a systematic review of the impact of estrogen–progestin combination therapies on the lipid profile of postmenopausal women found that the addition of a progestin only partially antagonized the favorable effects of estrogen on the lipid profile.<sup>
<xref ref-type="bibr" rid="bibr81-1933719112438061">81</xref>
</sup> Combined preparations containing NETA led to a reduction in HDL; however, triglycerides were also reduced, which may have beneficial cardiovascular effects.<sup>
<xref ref-type="bibr" rid="bibr81-1933719112438061">81</xref>
</sup> Furthermore, it is unclear if the observed reduction in HDL with NETA is large enough to be of clinical significance in premenopausal women.<sup>
<xref ref-type="bibr" rid="bibr81-1933719112438061">81</xref>
</sup>
</p>
<p>Estrogen is known to increase the synthesis of coagulation factors and increase the risk of thromboembolic disease, particularly during the first years of treatment. However, all trials that have examined clotting factors, specifically factor VII and fibrinogen, show a reduction from baseline or no change with combined estrogen and NETA treatment, suggesting that NETA does not have an adverse effect of thrombotic markers.<sup>
<xref ref-type="bibr" rid="bibr74-1933719112438061">74</xref>
</sup> Furthermore, the risk of venous thrombosis during the use of oral contraceptives seems to be higher with those products that contain progestins with less androgenic activity (eg, gestodene or desogestrel) compared with those that contain androgenic progestins, such as NETA or levonorgestrel.<sup>
<xref ref-type="bibr" rid="bibr82-1933719112438061">82</xref>
</sup> In addition, glucocorticoid activity stimulates thrombin-induced expression of the tissue factor and upregulates the procoagulatory and vasoconstrictory activity of lesioned arterial wall.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112438061">83</xref>
</sup> This observation suggests that the glucocorticoid activity of progestins, such as MPA, rather than their androgenic effect, could be involved in the development of cardiovascular disease.<sup>
<xref ref-type="bibr" rid="bibr15-1933719112438061">15</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section11-1933719112438061">
<title>Conclusions</title>
<p>The evidence from pharmacological and clinical studies indicates that NETA is a unique progestin that exerts both estrogenic and androgenic properties. The estrogenic activity is a result of the formation of estrogenic metabolites, mainly ethinyl estradiol, whereas the androgenic activity is AR mediated (<xref ref-type="fig" rid="fig3-1933719112438061">Figure 3</xref>). In addition, NETA shares both structural and functional similarities with tibolone, a treatment option in Europe, which prevents bone loss and improves vasomotor systems in women treated with GnRHa.</p>
<fig id="fig3-1933719112438061" position="float">
<label>Figure 3.</label>
<caption>
<p>Potential mechanism of action of NETA as an add-back therapy to GnRHa in women with endometriosis. NETA, after oral administration, is metabolized by the liver to various metabolites, including NET and EE. EE seems to be responsible for the alleviation of hypoestrogenic side effects of GnRH agonists, such as hot flashes and bone resorption. NET may exert antiproliferative effects on the endometrium via PR-mediated mechanisms, as well as AR-mediated anabolic effects on bones, although these effects have not yet been studied in women with endometriosis. NETA indicates norethindrone acetate; PR, progesterone receptor; AR, androgen receptor; NET, norethidnrone; EE, ethinyl estradiol.</p>
</caption>
<graphic alternate-form-of="fig3-1933719112438061" xlink:href="10.1177_1933719112438061-fig3.tif"/>
</fig>
<p>The estrogenic activity of NETA explains its beneficial effects on BMD and vasomotor symptoms in women when used as an add-back therapy for women who were treated with GnRHa. In addition, NETA exhibits strong endometrial antiproliferative effects, which may be beneficial in the endometriosis population. However, the benefits of NETA add-back therapy must be balanced with the risks that may be associated with the reductions in HDL and potential effects on breast proliferation. Additional studies examining low doses of NETA as add-back therapy are needed to determine the optimal dose in women with endometriosis.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719112438061">
<p>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: K.C. is an employee of Abbott and owns Abbott stock. E.S. has been a member of the speaker’s bureau and medical advisory board for Abbott and has been a member of the speaker’s bureau for Merck and EMF Serono. F.Z.S has nothing to disclose.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719112438061">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Medical writing support was provided by Jamie L. Kistler, of Complete Publication Solutions, LLC, which was funded by Abbott, and Amanda J. Fein, PhD of Abbott Laboratories. E.S. has received research grant support.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719112438061">
<label>1</label>
<citation citation-type="web">
<collab collab-type="author">European Society of Human Reproduction and Embryology</collab>. <comment>ESHRE guideline for the diagnosis and treatment of endometriosis. 2010</comment>; <ext-link ext-link-type="uri" xlink:href="http://guidelines.endometriosis.org/index.html">http://guidelines.endometriosis.org/index.html</ext-link>. <comment>Accessed July 27, 2010</comment>.</citation>
</ref>
<ref id="bibr2-1933719112438061">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gambone</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Mittman</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Scialli</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Winkel</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process</article-title>. <source>Fertil Steril</source>. <year>2002</year>;<volume>78</volume>(<issue>5</issue>):<fpage>961</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr3-1933719112438061">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olive</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone agonists for endometriosis</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>(<issue>11</issue>):<fpage>1136</fpage>–<lpage>1142</lpage>.</citation>
</ref>
<ref id="bibr4-1933719112438061">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surrey</surname>
<given-names>ES</given-names>
</name>
</person-group>. <article-title>Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?</article-title> <source>Curr Opin Obstet Gynecol</source>. <year>2010</year>;<volume>22</volume>(<issue>4</issue>):<fpage>283</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr5-1933719112438061">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agorastos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Vaitsi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Paschopoulos</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia</article-title>. <source>Maturitas</source>. <year>2004</year>;<volume>48</volume>(<issue>2</issue>):<fpage>125</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr6-1933719112438061">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olive</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>The role of add-back therapy in the United States</article-title>. <source>Drugs Today (Barc)</source>. <year>2005</year>;<volume>41</volume>(<issue>suppl A</issue>):<fpage>23</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr7-1933719112438061">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surrey</surname>
<given-names>ES</given-names>
</name>
</person-group>. <article-title>The role of progestins in treating the pain of endometriosis</article-title>. <source>J Minim Invasive Gynecol</source>. <year>2006</year>;<volume>13</volume>(<issue>6</issue>):<fpage>528</fpage>–<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr8-1933719112438061">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surrey</surname>
<given-names>ES</given-names>
</name>
</person-group>. <article-title>Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group</article-title>. <source>Fertil Steril</source>. <year>1999</year>;<volume>71</volume>(<issue>3</issue>):<fpage>420</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr9-1933719112438061">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hornstein</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Surrey</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Weisberg</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Casino</surname>
<given-names>LA</given-names>
</name>
</person-group>. <article-title>Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group</article-title>. <source>Obstet Gynecol</source>. <year>1998</year>;<volume>91</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr10-1933719112438061">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falcone</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lebovic</surname>
<given-names>DI</given-names>
</name>
</person-group>. <article-title>Clinical management of endometriosis</article-title>. <source>Obstet Gynecol</source>. <year>2011</year>;<volume>118</volume>(<issue>3</issue>):<fpage>691</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr11-1933719112438061">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mounsey</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Wilgus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Slawson</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Diagnosis and management of endometriosis</article-title>. <source>Am Fam Physician</source>. <year>2006</year>;<volume>74</volume>(<issue>4</issue>):<fpage>594</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr12-1933719112438061">
<label>12</label>
<citation citation-type="web">
<collab collab-type="author">ESHRE</collab>. <comment>ESHRE guideline for the diagnosis and treatment of endometriosis 2010</comment>; <ext-link ext-link-type="uri" xlink:href="http://guidelines.endometriosis.org/index.html">http://guidelines.endometriosis.org/index.html</ext-link>. <comment>Accessed July 27, 2010</comment>.</citation>
</ref>
<ref id="bibr13-1933719112438061">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuldeore</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Marx</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Chwalisz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smeeding</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Brook</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Add-back therapy use and its impact on LA persistence in patients with endometriosis</article-title>. <source>Curr Med Res Opin</source>. <year>2010</year>; <volume>26</volume>(<issue>3</issue>):<fpage>729</fpage>–<lpage>736</lpage>.</citation>
</ref>
<ref id="bibr14-1933719112438061">
<label>14</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Stanczyk</surname>
<given-names>FZ</given-names>
</name>
</person-group>. <article-title>Structure–function relationships, pharmacokinetics, and potency of orally and parenterally administered progestogens intervention</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</name>
</person-group>, ed. <source>Treatment of the Postmenopausal Woman: Basic and Clinical Aspects</source>. <edition>3rd ed</edition>. <publisher-loc>Burlington, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2007</year>:<fpage>779</fpage>–<lpage>798</lpage>.</citation>
</ref>
<ref id="bibr15-1933719112438061">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiegratz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kuhl</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Progestogen therapies: differences in clinical effects?</article-title> <source>Trends Endocrinol Metab</source>. <year>2004</year>;<volume>15</volume>(<issue>6</issue>):<fpage>277</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr16-1933719112438061">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kenemans</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Speroff</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group</article-title>. <source>Maturitas</source>. <year>2005</year>;<volume>51</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr17-1933719112438061">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albertazzi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bottazzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steel</surname>
<given-names>SA</given-names>
</name>
</person-group>. <article-title>Bone mineral density and depot medroxyprogesterone acetate</article-title>. <source>Contraception</source>. <year>2006</year>;<volume>73</volume>(<issue>6</issue>):<fpage>577</fpage>–<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr18-1933719112438061">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brauchli</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Jick</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Kraenzlin</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>CR</given-names>
</name>
</person-group>. <article-title>Use of depot medroxyprogesterone acetate and fracture risk</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2010</year>;<volume>95</volume>(<issue>11</issue>):<fpage>4909</fpage>–<lpage>4916</lpage>.</citation>
</ref>
<ref id="bibr19-1933719112438061">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schindler</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Campagnoli</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Druckmann</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Classification and pharmacology of progestins</article-title>. <source>Maturitas</source>. <year>2003</year>;<volume>46</volume>(<issue>suppl 1</issue>):<fpage>S7</fpage>–<lpage>S16</lpage>.</citation>
</ref>
<ref id="bibr20-1933719112438061">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Back</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Breckenridge</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>FE</given-names>
</name>
<etal/>
</person-group> <article-title>Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing</article-title>. <source>Clin Pharmacol Ther</source>. <year>1978</year>;<volume>24</volume>(<issue>4</issue>):<fpage>439</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr21-1933719112438061">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Back</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Breckenridge</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>FE</given-names>
</name>
<etal/>
</person-group> <article-title>Kinetics of norethindrone in women. II. Single-dose kinetics</article-title>. <source>Clin Pharmacol Ther</source>. <year>1978</year>;<volume>24</volume>(<issue>4</issue>):<fpage>448</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr22-1933719112438061">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanczyk</surname>
<given-names>FZ</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids</article-title>. <source>Contraception</source>. <year>1990</year>;<volume>42</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr23-1933719112438061">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhnz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Heuner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Humpel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Seifert</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Michaelis</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women</article-title>. <source>Contraception</source>. <year>1997</year>;<volume>56</volume>(<issue>6</issue>):<fpage>379</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr24-1933719112438061">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gentzschein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stanczyk</surname>
<given-names>FZ</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Formation of ethinyl estradiol in women during treatment with norethindrone acetate</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>(<issue>6</issue>):<fpage>2205</fpage>–<lpage>2207</lpage>.</citation>
</ref>
<ref id="bibr25-1933719112438061">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burkman</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Barnowski</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>LaGuardia</surname>
<given-names>KD</given-names>
</name>
</person-group>. <article-title>Association between efficacy and body weight or body mass index for two low-dose oral contraceptives</article-title>. <source>Contraception</source>. <year>2009</year>;<volume>79</volume>(<issue>6</issue>):<fpage>424</fpage>–<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr26-1933719112438061">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbieri</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Hormone treatment of endometriosis: the estrogen threshold hypothesis</article-title>. <source>Am J Obstet Gynecol</source>. <year>1992</year>;<volume>166</volume>(<issue>2</issue>):<fpage>740</fpage>–<lpage>745</lpage>.</citation>
</ref>
<ref id="bibr27-1933719112438061">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>Coregulator function: a key to understanding tissue specificity of selective receptor modulators</article-title>. <source>Endocr Rev</source>. <year>2004</year>;<volume>25</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr28-1933719112438061">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Nawaz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>O'Malley</surname>
<given-names>BW</given-names>
</name>
</person-group>. <article-title>Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen</article-title>. <source>Mol Endocrinol</source>. <year>1997</year>;<volume>11</volume>(<issue>6</issue>):<fpage>657</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr29-1933719112438061">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chwalisz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Demanno</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Winkel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis</article-title>. <source>Endocr Rev</source>. <year>2005</year>;<volume>26</volume>(<issue>3</issue>):<fpage>423</fpage>–<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr30-1933719112438061">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>HZ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>HA</given-names>
</name>
<etal/>
</person-group> <article-title>Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model</article-title>. <source>Bone</source>. <year>1997</year>;<volume>20</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr31-1933719112438061">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Ellman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dolker</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group</article-title>. <source>Obstet Gynecol</source>. <year>1999</year>;<volume>94</volume>(<issue>3</issue>):<fpage>330</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr32-1933719112438061">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genant</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group</article-title>. <source>Arch Intern Med</source>. <year>1997</year>;<volume>157</volume>(<issue>22</issue>):<fpage>2609</fpage>–<lpage>2615</lpage>.</citation>
</ref>
<ref id="bibr33-1933719112438061">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mashchak</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Dozono-Takano</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Comparison of pharmacodynamic properties of various estrogen formulations</article-title>. <source>Am J Obstet Gynecol</source>. <year>1982</year>;<volume>144</volume>(<issue>5</issue>):<fpage>511</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr34-1933719112438061">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prior</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Progesterone as a bone-trophic hormone</article-title>. <source>Endocr Rev</source>. <year>1990</year>;<volume>11</volume>(<issue>2</issue>):<fpage>386</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr35-1933719112438061">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rickard</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Iwaniec</surname>
<given-names>UT</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Bone growth and turnover in progesterone receptor knockout mice</article-title>. <source>Endocrinology</source>. <year>2008</year>;<volume>149</volume>(<issue>5</issue>):<fpage>2383</fpage>–<lpage>2390</lpage>.</citation>
</ref>
<ref id="bibr36-1933719112438061">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wells</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Tugwell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shea</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women</article-title>. <source>Endocr Rev</source>. <year>2002</year>;<volume>23</volume>(<issue>4</issue>):<fpage>529</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr37-1933719112438061">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallagher</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kable</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Goldgar</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen</article-title>. <source>Am J Med</source>. <year>1991</year>;<volume>90</volume>(<issue>2</issue>):<fpage>171</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr38-1933719112438061">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thijssen</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Long-term effects of progestins on bone quality and fractures</article-title>. <source>Gynecol Endocrinol</source>. <year>2007</year>;<volume>23</volume>(<issue>suppl 1</issue>):<fpage>45</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr39-1933719112438061">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Suppressive function of androgen receptor in bone resorption</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>(<issue>16</issue>):<fpage>9416</fpage>–<lpage>9421</lpage>.</citation>
</ref>
<ref id="bibr40-1933719112438061">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soule</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Prelevic</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ginsburg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Osteopenia as a feature of the androgen insensitivity syndrome</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1995</year>;<volume>43</volume>(<issue>6</issue>):<fpage>671</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr41-1933719112438061">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group> <article-title>Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>331</volume>(<issue>16</issue>):<fpage>1056</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr42-1933719112438061">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdalla</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Leggate</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hooke</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Prevention of bone mineral loss in postmenopausal women by norethisterone</article-title>. <source>Obstet Gynecol</source>. <year>1985</year>;<volume>66</volume>(<issue>6</issue>):<fpage>789</fpage>–<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr43-1933719112438061">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Livial: a review of clinical studies</article-title>. <source>Br J Obstet Gynaecol</source>. <year>1999</year>;<volume>106</volume>(<issue>suppl 19</issue>):<fpage>1</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr44-1933719112438061">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wishart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Need</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Philcox</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nordin</surname>
<given-names>BE</given-names>
</name>
</person-group>. <article-title>Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density</article-title>. <source>Arch Intern Med</source>. <year>1987</year>;<volume>147</volume>(<issue>4</issue>):<fpage>681</fpage>–<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr45-1933719112438061">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansen</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Riis</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Christiansen</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women</article-title>. <source>Metabolism</source>. <year>1990</year>;<volume>39</volume>(<issue>11</issue>):<fpage>1122</fpage>–<lpage>1126</lpage>.</citation>
</ref>
<ref id="bibr46-1933719112438061">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eiken</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kolthoff</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>SP</given-names>
</name>
</person-group>. <article-title>Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women</article-title>. <source>Bone</source>. <year>1996</year>;<volume>19</volume>(<issue>5 suppl</issue>):<fpage>191S</fpage>–<lpage>193S</lpage>.</citation>
</ref>
<ref id="bibr47-1933719112438061">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pors Nielsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Barenholdt</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hermansen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Munk-Jensen</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment</article-title>. <source>Br J Obstet Gynaecol</source>. <year>1994</year>;<volume>101</volume>(<issue>4</issue>):<fpage>319</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr48-1933719112438061">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosignani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Olive</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luciano</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Advances in the management of endometriosis: an update for clinicians</article-title>. <source>Hum Reprod Update</source>. <year>2006</year>;<volume>12</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr49-1933719112438061">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosignani</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Luciano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain</article-title>. <source>Hum Reprod</source>. <year>2006</year>;<volume>21</volume>(<issue>1</issue>):<fpage>248</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr50-1933719112438061">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hedon</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Mayenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Roux</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial</article-title>. <source>Hum Reprod</source>. <year>2004</year>;<volume>19</volume>(<issue>6</issue>):<fpage>1465</fpage>–<lpage>1471</lpage>.</citation>
</ref>
<ref id="bibr51-1933719112438061">
<label>51</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Roux</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Briot</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kolta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fechtenbaum</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>3 year-follow-up of bone mineral density after a randomised trial of 12-month treatment with a GnRH agonist (leuprorelin 3.75 mg) associated with 2 options of steroidal "Add-Back" regimens in patients with endometriosis</article-title>. <comment>Paper presented at: Conference title: 27th Annual Meeting of the American-Society-for-Bone-and-Mineral- Research, September 23-27, 2005, Nashville, TN</comment>, <publisher-loc>USA, Sponsor</publisher-loc>: <publisher-name>Amer Soc Bone &amp; Mineral Res</publisher-name>. <year>2005</year>.</citation>
</ref>
<ref id="bibr52-1933719112438061">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Utian</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Shoupe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bachmann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pinkerton</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Pickar</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>75</volume>(<issue>6</issue>):<fpage>1065</fpage>–<lpage>1079</lpage>.</citation>
</ref>
<ref id="bibr53-1933719112438061">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodwin</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Moinpour</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group> <article-title>Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>10</issue>):<fpage>1650</fpage>–<lpage>1656</lpage>.</citation>
</ref>
<ref id="bibr54-1933719112438061">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loprinzi</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Michalak</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Quella</surname>
<given-names>SK</given-names>
</name>
<etal/>
</person-group> <article-title>Megestrol acetate for the prevention of hot flashes</article-title>. <source>N Engl J Med</source>. <year>1994</year>;<volume>331</volume>(<issue>6</issue>):<fpage>347</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr55-1933719112438061">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhl</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Mechanisms of sex steroids. Future developments</article-title>. <source>Maturitas</source>. <year>2004</year>;<volume>47</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr56-1933719112438061">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Parsons</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Whitehead</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Wordsworth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stuart</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pryse-Davies</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study</article-title>. <source>Fertil Steril</source>. <year>1990</year>;<volume>53</volume>(<issue>3</issue>):<fpage>460</fpage>–<lpage>468</lpage>.</citation>
</ref>
<ref id="bibr57-1933719112438061">
<label>57</label>
<citation citation-type="book">
<collab collab-type="author">Activella [package insert]</collab>. <publisher-loc>Princeton, NJ</publisher-loc>: <publisher-name>Novo Nordisk</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr58-1933719112438061">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>RB</given-names>
</name>
</person-group>. <article-title>Steroid receptors and proliferation in the human breast</article-title>. <source>Steroids</source>. <year>2003</year>;<volume>68</volume>(<issue>10-13</issue>):<fpage>789</fpage>–<lpage>794</lpage>.</citation>
</ref>
<ref id="bibr59-1933719112438061">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soderqvist</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Isaksson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>von Schoultz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Carlstrom</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Skoog</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Proliferation of breast epithelial cells in healthy women during the menstrual cycle</article-title>. <source>Am J Obstet Gynecol</source>. <year>1997</year>;<volume>176</volume>(<issue>1 pt 1</issue>):<fpage>123</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr60-1933719112438061">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lundstrom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wilczek</surname>
<given-names>B</given-names>
</name>
<name>
<surname>von Palffy</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Soderqvist</surname>
<given-names>G</given-names>
</name>
<name>
<surname>von Schoultz</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Mammographic breast density during hormone replacement therapy: differences according to treatment</article-title>. <source>Am J Obstet Gynecol</source>. <year>1999</year>;<volume>181</volume>(<issue>2</issue>):<fpage>348</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr61-1933719112438061">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Svane</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Azavedo</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy</article-title>. <source>Fertil Steril</source>. <year>2004</year>;<volume>81</volume>(<issue>6</issue>):<fpage>1617</fpage>–<lpage>1623</lpage>.</citation>
</ref>
<ref id="bibr62-1933719112438061">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossouw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group> <article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>288</volume>(<issue>3</issue>):<fpage>321</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr63-1933719112438061">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beral</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Breast cancer and hormone-replacement therapy in the Million Women Study</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9382</issue>):<fpage>419</fpage>–<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr64-1933719112438061">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chlebowski</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>(<issue>15</issue>):<fpage>1684</fpage>–<lpage>1692</lpage>.</citation>
</ref>
<ref id="bibr65-1933719112438061">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyytinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dyba</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Pukkala</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ylikorkala</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland</article-title>. <source>Int J Cancer</source>. <year>2010</year>;<volume>127</volume>(<issue>1</issue>):<fpage>185</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr66-1933719112438061">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuedal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bjorndal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ursin</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women</article-title>. <source>Climacteric</source>. <year>2009</year>;<volume>12</volume>(<issue>3</issue>):<fpage>248</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr67-1933719112438061">
<label>67</label>
<citation citation-type="web">SEER Cancer Statistics Review, 1975-2007. National Cancer Institute Web site. <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2007/">http://seer.cancer.gov/csr/1975_2007/</ext-link>. <comment>Accessed July 29, 2011</comment>.</citation>
</ref>
<ref id="bibr68-1933719112438061">
<label>68</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Speroff</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Darney</surname>
<given-names>PD</given-names>
</name>
</person-group>, eds. <source>A Clinical Guide for Contraception</source>. <edition>4th ed</edition>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr69-1933719112438061">
<label>69</label>
<citation citation-type="journal">
<collab collab-type="author">Breast cancer and hormonal contraceptives: further results</collab>. <article-title>Collaborative Group on Hormonal Factors in Breast Cancer</article-title>. <source>Contraception</source>. <year>1996</year>;<volume>54</volume>(<issue>3 suppl</issue>):<fpage>1S</fpage>–<lpage>106S</lpage>.</citation>
</ref>
<ref id="bibr70-1933719112438061">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>A case-control study of the risk of breast cancer in relation to oral contraceptive use</article-title>. <source>Am J Epidemiol</source>. <year>1992</year>;<volume>136</volume>(<issue>12</issue>):<fpage>1437</fpage>–<lpage>1444</lpage>.</citation>
</ref>
<ref id="bibr71-1933719112438061">
<label>71</label>
<citation citation-type="journal">
<collab collab-type="author">Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies</collab>. <article-title>Collaborative Group on Hormonal Factors in Breast Cancer</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>347</volume>(<issue>9017</issue>):<fpage>1713</fpage>–<lpage>1727</lpage>.</citation>
</ref>
<ref id="bibr72-1933719112438061">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plu-Bureau</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Le</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Sitruk-Ware</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thalabard</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Mauvais-Jarvis</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease</article-title>. <source>Br J Cancer</source>. <year>1994</year>;<volume>70</volume>(<issue>2</issue>):<fpage>270</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr73-1933719112438061">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossouw</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Manson</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group> <article-title>Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>297</volume>(<issue>13</issue>):<fpage>1465</fpage>–<lpage>1477</lpage>.</citation>
</ref>
<ref id="bibr74-1933719112438061">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pohost</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Progesterone, progestins, and the heart</article-title>. <source>Rev Cardiovasc Med</source>. <year>2010</year>;<volume>11</volume>(<issue>4</issue>):<fpage>228</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr75-1933719112438061">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crews</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Khalil</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>1999</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1034</fpage>–<lpage>1040</lpage>.</citation>
</ref>
<ref id="bibr76-1933719112438061">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Earl</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Sugiura</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Montefiori</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group> <article-title>Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140</article-title>. <source>J Virol</source>. <year>2001</year>;<volume>75</volume>(<issue>2</issue>):<fpage>645</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr77-1933719112438061">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Sarrel</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Poole-Wilson</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro</article-title>. <source>Eur J Pharmacol</source>. <year>1992</year>;<volume>211</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr78-1933719112438061">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minshall</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Pavcnik</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Browne</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Hermsmeyer</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Nongenomic vasodilator action of progesterone on primate coronary arteries</article-title>. <source>J Appl Physiol</source>. <year>2002</year>;<volume>92</volume>(<issue>2</issue>):<fpage>701</fpage>–<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr79-1933719112438061">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedersen</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Dalsgaard</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lund</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Nilas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ottesen</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand White rabbit</article-title>. <source>Climacteric</source>. <year>2004</year>;<volume>7</volume>(<issue>1</issue>):<fpage>12</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr80-1933719112438061">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosano</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Chierchia</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>36</volume>(<issue>7</issue>):<fpage>2154</fpage>–<lpage>2159</lpage>.</citation>
</ref>
<ref id="bibr81-1933719112438061">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Godsland</surname>
<given-names>IF</given-names>
</name>
</person-group>. <article-title>Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>75</volume>(<issue>5</issue>):<fpage>898</fpage>–<lpage>915</lpage>.</citation>
</ref>
<ref id="bibr82-1933719112438061">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhl</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Effects of progestogens on haemostasis</article-title>. <source>Maturitas</source>. <year>1996</year>;<volume>24</volume>(<issue>1-2</issue>):<fpage>1</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr83-1933719112438061">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herkert</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kuhl</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sandow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Busse</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schini-Kerth</surname>
<given-names>VB</given-names>
</name>
</person-group>. <article-title>Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>23</issue>):<fpage>2826</fpage>–<lpage>2831</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>